DNA — Ginkgo Bioworks Holdings, Inc.
—
NYSE ·
Health Care ·
Biotechnology ·
CIK 1830214 ·
Last close
$13.00
Market Cap
$719.99M
52W High
$18.22
52W Low
$5.37
ADV30
2,747,713
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 20,156,000 | 18,437,000 | -58,548,000 | -46,710,000 | 990,046,000 | 84,535,000 | 569,762,000 |
| Mar 2026 | 19,474,000 | 16,376,000 | -71,374,000 | -82,587,000 | 1,033,075,000 | 143,864,000 | 589,922,000 |
| Dec 2025 | 33,396,000 | 26,095,000 | -70,046,000 | -80,751,000 | 1,119,696,000 | 167,202,000 | 611,106,000 |
| Sep 2025 | 38,837,000 | 26,035,000 | -88,272,000 | -80,755,000 | 1,189,165,000 | 111,065,000 | 629,382,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-178,360,000
Investing CF
$56,502,000
Financing CF
$34,550,000
CapEx
$-4,595,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.69
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-6,279,617,000
Inventory
—
Receivables
$13,013,000
ST Investments
$217,628,000
EBIT TTM
$-297,960,000
Pretax Income TTM
$-295,480,000
Interest Exp TTM
—
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$132,421,000
EBITDA
$-261,624,992
Free Cash Flow
$-72,398,248
Enterprise Value
$556,496,896
Total Cash
$302,163,008
Total Debt
$404,112,992
Shares Out
55,383,808
Trailing EPS
$-5.33
Book Value
$6.60
ROE
-59.9%
ROA
-16.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 170,155,000 | -303,880,000 | -312,763,000 | 1,119,696,000 | 611,106,000 | 508,590,000 | -171,059,000 |
| Dec 2024 | 227,043,000 | -487,727,000 | -547,029,000 | 1,377,449,000 | 661,391,000 | 716,058,000 | -319,585,000 |
| Dec 2023 | 251,455,000 | -768,196,000 | -892,869,000 | 1,665,342,000 | 568,190,000 | 1,097,152,000 | -295,500,000 |
| Dec 2022 | 477,706,000 | -2,208,952,000 | -2,104,929,000 | 2,539,321,000 | 803,044,000 | 1,736,277,000 | -252,198,000 |
TTM Snapshot
Revenues TTM
$141,311,000
NetIncome TTM
$-304,393,000
OpCashFlow TTM
—
Assets (Latest)
$1,033,075,000
Forward EPS
$-2.90
Max Pain — expiry 2026-10-16
max pain strike: $10.00 · spot: $13.00 · call oi: 6,581 · put oi: 2,282
Expected Move to 2026-10-16:
±$1.60
(12.31%) —
implied range
$11.40 –
$14.60
· ATM straddle on $13.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PRME | Prime Medicine, Inc. | $723.69M | $3.99 | — |
| FDMT | 4D Molecular Therapeutics, Inc. | $736.41M | $13.33 | — |
| SLDB | Solid Biosciences Inc. | $736.64M | $6.87 | — |
| ATTO | Attovia Therapeutics, Inc. | $740.01M | $16.21 | — |
| CADL | Candel Therapeutics, Inc. | $760.59M | $9.94 | — |
News headlines (Yahoo Finance, 1h cache)
Araceli Biosciences and Ginkgo Bioworks Bring Cellular Imaging at Scale to Nebula's Lab-in-the-Loop
2026-10-08 10:00 · Yahoo
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Falls Amid Market Uptick: What Investors Need to Know
2026-10-01 21:15 · Yahoo
Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
2026-09-23 22:15 · Yahoo
Ginkgo Bioworks Holdings, Inc. (DNA) Rises As Market Takes a Dip: Key Facts
2026-09-16 22:15 · Yahoo
Ginkgo Datapoints Announces Partnership with TuneLab to Close the Gap between AI Models and Lab Data
2026-09-16 13:52 · Yahoo
Ginkgo Bioworks Joins ARPA-H GIVE Program to Build Autonomous Manufacturing System for Individualized RNA Medicines
2026-09-10 12:00 · Yahoo
The Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Sales Forecasts
2026-05-13 11:41 · Yahoo
Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium
2026-09-29 12:00 · Yahoo
Ginkgo Bioworks Q2 Earnings Call Highlights
2026-08-08 04:03 · Yahoo
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery
2026-05-26 16:33 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.